Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 12/2006

01-12-2006 | Article

Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward

Authors: A. H. Gifford, K. B. Kirkland

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2006

Login to get access

Abstract

Nosocomial diarrhea caused by Clostridium difficile causes significant morbidity and mortality in an increasing proportion of hospitalized patients annually. This case-control study of patients admitted to the hematology-oncology ward of a tertiary academic medical center over a 2-year period demonstrates that patients with Clostridium difficile-associated diarrhea (CDAD) were 22 times more likely than ward-matched controls with diarrhea to have received any antibiotic either during hospitalization or in the month preceding admission (p < 0.005), and they were nearly three times as likely as controls to have received a cephalosporin during the same period (p < 0.005). Diarrhea among lung cancer patients was approximately three times more likely to be caused by this organism than to be due to other causes (p = 0.04). A trend towards CDAD patients receiving higher numbers of different antibiotics during hospitalization (3.3 vs. 2.6, 95%CI −1.42–0.02, p = 0.06) was noted. Administration of interleukin-2 either during hospitalization or in the 30 days preceding admission was seven times more likely to have occurred in CDAD cases (p = 0.04), raising the question of whether or not this agent increases risk.
Literature
1.
go back to reference McFarland LV, Mulligan ME, Kwok RY, Stamm WE (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320:204–210PubMedCrossRef McFarland LV, Mulligan ME, Kwok RY, Stamm WE (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320:204–210PubMedCrossRef
2.
go back to reference Shapiro M, Schwaber MJ, Simhon A, Block C, Roval V, Ferderber N (2000) Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital. Eur J Clin Microbiol Infect Dis 19:9–15CrossRef Shapiro M, Schwaber MJ, Simhon A, Block C, Roval V, Ferderber N (2000) Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital. Eur J Clin Microbiol Infect Dis 19:9–15CrossRef
3.
go back to reference Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN (1992) Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 166:561–567PubMed Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN (1992) Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 166:561–567PubMed
4.
go back to reference Gorschlüter M, Glasmacher A, Hahn C, Schakowski F, Marklein G, Sauerbruch T, Ziske C, Molitor E, Schmidt-Wolf IGH (2003) Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 33:786–791CrossRef Gorschlüter M, Glasmacher A, Hahn C, Schakowski F, Marklein G, Sauerbruch T, Ziske C, Molitor E, Schmidt-Wolf IGH (2003) Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 33:786–791CrossRef
5.
go back to reference Dettenkofer M, Ebner W, Bertz H, Babikir R, Finke J, Frank U, Rüden H, Daschner FD (2003) Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transpl 31:795–801CrossRef Dettenkofer M, Ebner W, Bertz H, Babikir R, Finke J, Frank U, Rüden H, Daschner FD (2003) Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transpl 31:795–801CrossRef
6.
go back to reference Husain A, Aptaker L, Spriggs DR, Barakat RR (1998) Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel containing chemotherapy regimens. Gynecol Oncol 71:104–107PubMedCrossRef Husain A, Aptaker L, Spriggs DR, Barakat RR (1998) Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel containing chemotherapy regimens. Gynecol Oncol 71:104–107PubMedCrossRef
7.
go back to reference Emoto M, Kawarabayashi T, Hachisuga T, Eguchi F, Shirakawa K (1996) Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 61:369–372PubMedCrossRef Emoto M, Kawarabayashi T, Hachisuga T, Eguchi F, Shirakawa K (1996) Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 61:369–372PubMedCrossRef
8.
go back to reference Hornbuckle K, Chak A, Lazarus HM, Cooper GS, Sparano J, Kutteh LA, Gucalp R, Carlisle PS, Parker P, Salata RA (1998) Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 9:307–311PubMedCrossRef Hornbuckle K, Chak A, Lazarus HM, Cooper GS, Sparano J, Kutteh LA, Gucalp R, Carlisle PS, Parker P, Salata RA (1998) Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients. Ann Oncol 9:307–311PubMedCrossRef
9.
go back to reference Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA (2005) Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Cont Hosp Epidem 26:680–684CrossRef Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA (2005) Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Cont Hosp Epidem 26:680–684CrossRef
10.
go back to reference Sohn S, Climo M, Diekema D, Fraser V, Herwaldt L, Marino S, Noskin G, Perl T, Song X, Tokars J, Warren D, Wong E, Yokoe DS, Zembower T, Sepkowitz KA (2005) Varying rates of Clostridium difficile-associated diarrhea at prevention epicenter hospitals. Infect Cont Hosp Epidem 26:676–679CrossRef Sohn S, Climo M, Diekema D, Fraser V, Herwaldt L, Marino S, Noskin G, Perl T, Song X, Tokars J, Warren D, Wong E, Yokoe DS, Zembower T, Sepkowitz KA (2005) Varying rates of Clostridium difficile-associated diarrhea at prevention epicenter hospitals. Infect Cont Hosp Epidem 26:676–679CrossRef
11.
go back to reference Blot E, Escande MC, Besson D, Barbut F, Granpeix C, Asselain B, Falcou MC, Pouillart P (2003) Outbreak of Clostridium difficile-related diarrhea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 53:187–192PubMedCrossRef Blot E, Escande MC, Besson D, Barbut F, Granpeix C, Asselain B, Falcou MC, Pouillart P (2003) Outbreak of Clostridium difficile-related diarrhea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 53:187–192PubMedCrossRef
12.
go back to reference Turgeon DK, Novicki TJ, Quick J, Carlson L, Miller P, Ulness B, Cent A, Ashley R, Larson A, Coyle M, Limaye AP, Cookson BT, Fritsche TR (2003) Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. J Clin Microbiol 41:667–670PubMedCrossRef Turgeon DK, Novicki TJ, Quick J, Carlson L, Miller P, Ulness B, Cent A, Ashley R, Larson A, Coyle M, Limaye AP, Cookson BT, Fritsche TR (2003) Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. J Clin Microbiol 41:667–670PubMedCrossRef
13.
go back to reference Nelson DE, Auerbach SB, Baltch AL, Desjardin E, Beck-Sague C, Rheal C, Smith RP, Jarvis WR (1994) Epidemic Clostridium difficile-associated diarrhoea: role of second and third generation cephalosporins. Infect Cont Hosp Epidem 15:88–94CrossRef Nelson DE, Auerbach SB, Baltch AL, Desjardin E, Beck-Sague C, Rheal C, Smith RP, Jarvis WR (1994) Epidemic Clostridium difficile-associated diarrhoea: role of second and third generation cephalosporins. Infect Cont Hosp Epidem 15:88–94CrossRef
14.
go back to reference Buchner AM, Sonnenberg A (2002) Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. Digest Dis Sci 47:201–207PubMedCrossRef Buchner AM, Sonnenberg A (2002) Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. Digest Dis Sci 47:201–207PubMedCrossRef
15.
go back to reference Rosenberg SA, White DE, Kammula US (1998) Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83:797–805PubMedCrossRef Rosenberg SA, White DE, Kammula US (1998) Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83:797–805PubMedCrossRef
16.
go back to reference Daubener W et al (1988) Clostridium difficile toxins A and B inhibit human immune responses in vitro. Infect Immune 56:1107–1112 Daubener W et al (1988) Clostridium difficile toxins A and B inhibit human immune responses in vitro. Infect Immune 56:1107–1112
17.
go back to reference Guyot A, Barrett SP (2001) What is an appropriate control group to identify risk factors for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 48:747–748PubMedCrossRef Guyot A, Barrett SP (2001) What is an appropriate control group to identify risk factors for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 48:747–748PubMedCrossRef
Metadata
Title
Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward
Authors
A. H. Gifford
K. B. Kirkland
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2006
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-006-0220-1

Other articles of this Issue 12/2006

European Journal of Clinical Microbiology & Infectious Diseases 12/2006 Go to the issue

Announcements

Announcements

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.